Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

NCT07187115 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiveness compared to PFA of Pulmonary Veins and LA Posterior Wall (PVI+ PWA) in the treatment of de novo symptomatic drug-refractory persistent atrial fibrillation (PersAF).

Interventions

  • DEVICE FARAPOINT Pulsed Field Ablation System
  • DEVICE OptiMap System (non-ablative)
  • DEVICE FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System

Study Locations (20)

California

  • Alta Bates Summit Medical Center — Oakland
  • Stanford University Medical Center — Palo Alto
  • Pacific Heart Institute — Santa Monica

Arizona

  • Mercy Gilbert Medical Center — Gilbert
  • Banner University Medical Center — Phoenix

Georgia

  • Piedmont Athens Regional — Athens
  • Emory University Hospital — Atlanta

New York

  • Mount Sinai Medical Center — New York
  • Good Samaritan - Suffern — Suffern

Alabama

  • Grandview Medical Center — Birmingham

Arkansas

  • Arrhythmia Research Group — Jonesboro

Idaho

  • St. Luke's Idaho Cardiology Associates — Boise

Illinois

  • Endeavor Hospital — Glenview

Trial Details

FieldValue
Enrollment Target 699 participants
Start Date 2025-11-07
Est. Completion 2030-12
Phase NA

Sponsor

Boston Scientific Corporation

120 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07187115

The ClinicalTrials.gov registry entry for NCT07187115 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 699 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 120 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 3 interventions — of which FARAPOINT Pulsed Field Ablation System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07187115 reports 20 study locations spanning 15 distinct geographic areas — top geographies include California, Arizona, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07187115 about?

NCT07187115 is a clinical study titled "A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation". The purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiveness compared to PFA ...

What is the current status of trial NCT07187115?

This trial is currently recruiting. It is a NA study. The enrollment target is 699 participants. The study started on 2025-11-07. Estimated completion is 2030-12.

What conditions does trial NCT07187115 study?

This clinical trial studies the following conditions: Atrial Fibrillation (AF), Persistant Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07187115?

The interventions under investigation include: FARAPOINT Pulsed Field Ablation System (DEVICE), OptiMap System (non-ablative) (DEVICE), FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07187115?

This trial is sponsored by Boston Scientific Corporation, which has 120 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07187115 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial